|
|
| Commercial Reasonableness of Physician Compensation—Analytical Update with MACRA |
Product Discontinued: 04/12/23 (DR)
CPE Credit
Program Type: VideoCast (Audio,Video, PPT Presentation)
Program Level: Overview
Prerequisites: Learning activity level that provides a general review of a subject area from a broad perspective
Advanced Preparation: None
Delivery Method: Group Internet-Based
CPE Credits: Two (2) Hour
Fields of Study: Business Law; Economics |
Item
Number: 17PHCCHI0608A
Shipping Weight: 0lbs. 0oz. |
| Price:
$110.00 |
|
|
| Sorry, this product is no longer available. |
 |
|
|
Program Description
With recent healthcare reform initiatives, a major paradigm shift is taking place in the healthcare delivery system. The passage and implementation of MACRA, as well as legislative discussion regarding the viability and sustainability of current fraud and abuse laws, may significantly change the requisite analysis required to determine whether a physician compensation arrangement does not exceed FMV and is a commercially reasonable (CR) transaction. This session will focus on the potential impact of MACRA and other reform initiatives on related changes in the methodology and analytical thresholds for the CR of physician compensation arrangements, and valuation professionals with the tools to understand and thrive in this paradigm shift.
Learning Objectives
After completing this webinar, attendees will be able to:
- Articulate the various definitions of Commercial Reasonableness as promulgated by federal statutes, regulations, and case law
- Identify and describe the most recent federal fraud and abuse cases related to Commercial Reasonableness and physician compensation
- Describe the potential challenges surrounding the development of a Commercial Reasonableness analysis in the current volatile healthcare reimbursement environment, which is shifting payment from a volume-based to a value-based structure
Who Should Attend
Valuation professionals, attorneys, hospital and health system c-suite executives (e.g., CEOs, CFOs, COOs), and healthcare consultants
Presenter(s)
Todd Zigrang
Mr. Todd Zigrang is the President of Health Capital Consultants, where he focuses on the areas of valuation and financial analysis for hospitals, physician practices, and other healthcare enterprises. Mr. Zigrang has over 20 years of experience providing valuation, financial, transaction and strategic advisory services nationwide in over 1,000 transactions and joint ventures. Mr. Zigrang is also considered an expert in the field of healthcare compensation for physicians, executives and other professionals.
Mr. Zigrang is the co-author of the “Adviser’s Guide to Healthcare – 2nd Edition” (AICPA, 2015), numerous chapters in legal treatises and anthologies, and peer-reviewed and industry articles such as: The Accountant's Business Manual, Business Valuation Review (ASA), and NACVA QuickRead. Additionally, Mr. Zigrang has served as faculty before professional and trade associations including the ABA, NACVA, IBA, HFMA, ACHE, Physician Hospitals of America, and the CPA Leadership Institute.
Robert James Cimasi
Mr. Robert James Cimasi, MHA, ASA, FRICS, MCBA, CVA, CM&AA, serves as CEO of HCC, a nationally recognized healthcare financial and economic consulting firm headquartered in St. Louis, MO, serving clients in 49 states since 1993. Mr. Cimasi has over 35 years of experience in serving clients, with a professional focus on the financial and economic aspects of healthcare service sector entities including: valuation consulting and capital formation services; healthcare industry transactions including joint ventures, mergers, acquisitions, and divestitures; litigation support & expert testimony; and, certificate-of-need and other regulatory and policy planning consulting.
Mr. Cimasi serves on the Editorial Board of The Value Examiner of NACVA. In 2006, Mr. Cimasi was honored with the prestigious “Shannon Pratt Award in Business Valuation” conferred by the IBA. In 2016, Mr. Cimasi was named a Pioneer of the Profession as part of the recognition of the NACVA Industry Titans awards. |
|
|
